Haut
  • Theranostic radioimmunotherapy (RIT) combined with immunotherapy : The best way to go ? Jean-François Chatal*, Med Res Innov, 2017 doi : 10.15761/MRI.1000119
  • Barbet J, Arlicot N, Gaugler MH, Chérel M, Guilloteau D, Kraeber-Bodéré F. Editorial : Innovative Radiopharmaceuticals in Oncology and Neurology. Front Med (Lausanne). 2017 Jan 11 ;3:74. doi : 10.3389/fmed.2016.00074. eCollection 2016.
  • Comparison of Immuno-PET of CD138 and PET imaging with 64CuCl2 and 18F-FDG in a preclinical syngeneic model of multiple myeloma. C. Bailly et al. (accpeté pour publication dans Oncotarget)
  • “Immuno-PET for Clinical Theranostic Approaches« . Clément Bailly, Pierre-François Cléry, Alain Faivre-Chauvet, Mickaël Bourgeois, François Guérard, Ferid Haddad, Jacques Barbet, Michel Chérel, Françoise Kraeber-Bodéré, Thomas Carlier and Caroline Bodet-Milin. International Journal of Molecular Sciences 2017, 18 (1), 57 2017
  • Bailly C, Bodet-Milin C, Rousseau C, Faivre-Chauvet A, Kraeber-Bodéré F, Barbet J. EJNMMI radiopharm. chem. (2017) 2 : 6. https://doi.org/10.1186/s41181-017-0026-8
  • van Leeuwen FWB, Cornelissen B, Caobelli F, Evangelista L, Rbah-Vidal L, Del Vecchio S, Xavier C, Barbet J, de Jong M. EJNMMI radiopharm. chem. (2017) 2 : 15. https://doi.org/10.1186/s41181-017-0034-8
  • Bourgeois M, Bailly C, Guerard F, Cherel M, Faivre-Chauvet A, Kraeber-Bodere F, Bodet-Milin C. Radioimmunoconjugates for treating cancer : recent advances and current opportunities. Expert Opin Biol Ther 2017, 4 : 1-7 IF 3.684
  • Frindel M, Le Saëc P, Beyler M, Navarro AS, Saï-Maurel C, Alliot C, Chérel M, Gestin JF, Faivre-Chauvet A, Tripier R. Cyclam te1pa for 64Cu PET imaging. Bioconjugation to antibody, radiolabeling and preclinical application in xenografted colorectal cancer. RSC Adv. 2017, 7 : 9272 IF 3.108
  • Jamet B, Carlier T, Campion L, Bompas E, Girault S, Borrely F, Ferrer L, Rousseau M, Venel Y, Kraeber-Bodéré F, Rousseau C. Initial FDG-PET/CT predicts survival in adults ewing sarcoma family of tumors Oncotarget 2017, 8:77050-77060 IF 5.168

Communications orales:

  • Conférence annuelle ESVONC (European Society of Veterinary Oncology) (Lyon, France) – Avril 2017 – “ Targeting CD22 in spontaneous diffuse large B-cell lymphoma bearing dogs : quantitative imaging (immuno-SPECT) and dosimetric approach in preparation of radioimmunotherapy (RIT) “ F. Morio1, N. Chouin1,2, F. Nguyen1, M. Berthaud2, M. Fusellier3, C. Bodet-Milin2,4, M. Roussel1, S. Becavin1, J. Abadie1, L. Ferrer2,5, C. Ibisch1,2, F. Davodeau2
  • Conférence EANM 2017 (Vienne, Autriche)- Octobre 2017 – « B-cell lymphoma radioimmunotherapy : effect of co-infusion of cold and radiolabelled antibody on absorbed doses to healthy tissues and tumours, a preclinical study in dogs ». F. Morio1,2, C. Ibisch1,2, F. Nguyen1,3, M. Berthaud2, J. Abadie1,3, A. Vidal5, M. Bourgeois2,4,5, K. Bernardeau7, S. Becavin1, M. Roussel1, L. Ferrer2,6, C. Bodet-Milin2,4, N. Chouin1,2, F. Davodeau2
  • J. Barbet, Conf invité Pretargeting in the Context of Theranostics and Companion Diagnostics, CME 5 : Theranostics and Companion Drugs, EANM, Vienna (Autriche) October 21-25, 2017
  • Chérel M, Anticorps monoclonaux : mise en place d’une filière nationale : le point de vue d’Arronax, 11e Journées du cancéropole Grand Ouest, Vannes, France, June 29-30 2017